$SRNE If STI-1499 doesn't pan out in clinical trials, all of Sorrento's recent gains will evaporate. Investors should ask themselves if they're willing to take the risk of losing half of their money or even more in exchange for the possibility of making several times their initial investment. My answer to this question is a resounding "no." I think that there are too many uncertainties for Sorrento to be a compelling stock to buy at this point.
  • 2